Developer docs
API playgroundTry for free, no card

Search company profiles

LogicBio Therapeutics

Full company profile

uuid0004rla

Namestring
LogicBio Therapeutics
Legal namestring
LogicBio Therapeutics
Websiteurl
logicbio.com
Company typeenum
Public
Founded yearint
2015
Descriptiontext

LogicBio Therapeutics was a clinical-stage genetic medicine company founded in 2014 and headquartered in Lexington, Massachusetts. The company developed gene therapy and genome editing treatments targeting rare genetic diseases, with a pipeline focused on monogenic disorders including methylmalonic acidemia (MMA) and hemophilia B. It served patients with rare inherited conditions that lacked adequate treatment options, positioning itself within the orphan disease segment of the gene therapy market.

The company's core technology centered on proprietary platforms including the GeneRide genome editing platform (a homologous recombination-based approach for in vivo gene integration) and the sAAVy capsid technology for tissue-targeted AAV delivery. These platforms formed the technical foundation of the company's pipeline and represented its primary intellectual property assets. LogicBio operated with 51-100 employees and maintained research collaborations with academic institutions in the gene therapy field, including its founding institutions. The company went public on NASDAQ under ticker LOGC in 2018 to fund clinical advancement of its pipeline.

LogicBio's business model was that of a pre-commercial clinical-stage biotech. The company generated revenue primarily through collaboration and license agreements rather than product sales, consistent with the $43 million in reported revenue that likely represents one-time license or milestone payments. With a net loss of $29 million, the company's economics reflected the heavy R&D investment typical of clinical-stage gene therapy developers. In 2022, LogicBio was acquired by Alexion Pharmaceuticals (now part of AstraZeneca Rare Disease), and it now operates as a subsidiary contributing gene therapy and genome editing capabilities to AstraZeneca's rare disease portfolio.

Short descriptiontext

LogicBio Therapeutics was a clinical-stage genetic medicine company developing gene therapy and genome editing treatments for rare genetic diseases, acquired by Alexion (AstraZeneca Rare Disease) in 2022.

Operating statusenum
Acquired
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersFoster City, United States
HQ citystring
Foster City
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
gene therapy development, genome editing platforms, rare disease therapeutics, AAV vector technology, genetic medicine research
Industry3 codes
PRIMARYHLAAACAE
Gene Therapy for Rare/Monogenic Diseases
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAAACAA
AAV Vector Gene Therapy Developers
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAAACAD
Genome Editing Gene Therapies (CRISPR/TALEN/ZFN; in vivo/ex vivo)
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
NAICS code2 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Biological Product (except Diagnostic) Manufacturing325414
SIC code1 code
  • Biological Products, (No Disgnostic Substances)2836
Product category
Gene Therapy & Genome Editing Therapeutics
Social media profiles2 records
Revenue model1 record
1Gene therapy product revenue
TypeOne Time License
Description

LogicBio Therapeutics generated revenue through the development and commercialization of gene therapy treatments for genetic diseases.

defenseworld.net
Cost components3 values
Personnel, Technology or R&D, Operations
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

LogicBio Therapeutics developed gene therapy vectors and genome editing treatments targeting rare genetic and infectious diseases. The company leveraged proprietary AAV-based delivery technology to create therapies for previously incurable inherited conditions, operating as a clinical-stage genetic medicine company prior to its 2022 acquisition by Alexion.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

LogicBio Therapeutics was a genetic medicine company that developed genome editing and gene therapy treatments for genetic diseases. The company operated from Lexington, Massachusetts. In 2022, LogicBio was acquired by Alexion (AstraZeneca Rare Disease). The company had approximately $43 million in revenue and was developing treatments in the gene therapy space. Fred Chereau served as President and CEO of LogicBio prior to the acquisition.

Product and service2 records
1Gene Therapy Treatments
CategoryGene Therapy Therapeutics
Description

LogicBio Therapeutics developed gene therapy treatments for patients with rare genetic diseases, leveraging proprietary genome editing and AAV-based delivery technology to address previously incurable inherited conditions.

2Genome Editing Technologies
CategoryGenome Editing Platform
Description

LogicBio Therapeutics' proprietary genome editing technologies formed a core component of the company's genetic medicine platform for treating rare genetic diseases, including genome editing approaches such as those for rare inherited disorders.

Scale indicator4 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2022-01-01
Description

LogicBio Therapeutics was acquired by Alexion in 2022. This acquisition brought LogicBio's gene therapy capabilities under Alexion's rare disease portfolio, with former LogicBio CEO Fred Chereau transitioning to Senior Vice President at Alexion - AstraZeneca Rare Disease and subsequently to CEO of Sensorion.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight3 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Pioneer in CRISPR/Cas9 genome editing therapeutics for rare genetic diseases including sickle cell disease and beta thalassemia. Directly comparable gene editing platform approach with overlapping indications.

TypeBroad incumbent
Description

Established gene therapy player with approved products for Duchenne muscular dystrophy. Broader incumbent with commercial rare disease gene therapy portfolio and significant revenue.

TypeEmerging player
Description

Clinical-stage AAV gene therapy company targeting rare CNS disorders. Comparable platform approach with similar stage of development and rare monogenic disease focus.

TypeEmerging player
Description

Gene therapy company developing AAV-based treatments for rare ophthalmologic and CNS diseases. Comparable modality (AAV gene therapy) and rare disease positioning.

TypeEmerging player
Description

Clinical-stage gene therapy company developing AAV-based treatments for rare CNS diseases. Comparable platform, similar rare disease focus, and overlapping patient populations.

6bluebird bio
TypeDirect peer
Description

Direct competitor developing gene therapies and genome editing approaches for rare genetic diseases, including hemoglobinopathies and neurological conditions. Highly comparable in modality, indication focus, and target patient population.

TypeDirect peer
Description

Gene therapy company focused on AAV-based treatments for rare diseases, including CNS and metabolic disorders. Directly comparable platform approach targeting monogenic conditions with high unmet need.

TypeDirect peer
Description

Genome editing company developing CRISPR-based and engineered Cas9 therapies for rare genetic diseases including inherited retinal disorders. Comparable genome editing modality and rare disease focus.

TypeBroad incumbent
Description

Acquired by Roche, Spark is a gene therapy pioneer (Luxturna) focused on rare inherited diseases. Larger platform with approved products, making it a broad incumbent in the rare disease gene therapy space.

TypeDirect peer
Description

AAV gene therapy platform company developing treatments for rare diseases including retinal, metabolic, and neuromuscular conditions. Comparable AAV vector technology and rare disease focus.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks4 records

Each record includes

Headline, Details, Source

Key highlights5 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds5 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors8 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

LogicBio Therapeutics

Gene Therapy & Genome Editing Therapeuticslogicbio.com

LogicBio Therapeutics was a clinical-stage genetic medicine company developing gene therapy and genome editing treatments for rare genetic diseases, acquired by Alexion (AstraZeneca Rare Disease) in 2022.

What LogicBio Therapeutics does

LogicBio Therapeutics was a clinical-stage genetic medicine company founded in 2014 and headquartered in Lexington, Massachusetts. The company developed gene therapy and genome editing treatments targeting rare genetic diseases, with a pipeline focused on monogenic disorders including methylmalonic acidemia (MMA) and hemophilia B. It served patients with rare inherited conditions that lacked adequate treatment options, positioning itself within the orphan disease segment of the gene therapy market.

The company's core technology centered on proprietary platforms including the GeneRide genome editing platform (a homologous recombination-based approach for in vivo gene integration) and the sAAVy capsid technology for tissue-targeted AAV delivery. These platforms formed the technical foundation of the company's pipeline and represented its primary intellectual property assets. LogicBio operated with 51-100 employees and maintained research collaborations with academic institutions in the gene therapy field, including its founding institutions. The company went public on NASDAQ under ticker LOGC in 2018 to fund clinical advancement of its pipeline.

LogicBio's business model was that of a pre-commercial clinical-stage biotech. The company generated revenue primarily through collaboration and license agreements rather than product sales, consistent with the $43 million in reported revenue that likely represents one-time license or milestone payments. With a net loss of $29 million, the company's economics reflected the heavy R&D investment typical of clinical-stage gene therapy developers. In 2022, LogicBio was acquired by Alexion Pharmaceuticals (now part of AstraZeneca Rare Disease), and it now operates as a subsidiary contributing gene therapy and genome editing capabilities to AstraZeneca's rare disease portfolio.

LogicBio Therapeutics firmographics

Firmographics
Name
LogicBio Therapeutics
Legal name
LogicBio Therapeutics
Website
https://logicbio.com
Company type
Public
Founded year
2015
Operating status
Acquired
Headcount range
51–100 employees
Short description
LogicBio Therapeutics was a clinical-stage genetic medicine company developing gene therapy and genome editing treatments for rare genetic diseases, acquired by Alexion (AstraZeneca Rare Disease) in 2022.
Ownership category
akta.pro rank

LogicBio Therapeutics industry classification

Industry
Product category
Gene Therapy & Genome Editing Therapeutics
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414)
SIC
Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAAACAE
Gene Therapy for Rare/Monogenic Diseases
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAAACAA
AAV Vector Gene Therapy Developers
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAAACAD
Genome Editing Gene Therapies (CRISPR/TALEN/ZFN; in vivo/ex vivo)
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)

Keywords

  • Gene therapy development
  • Genome editing platforms
  • Rare disease therapeutics
  • AAV vector technology
  • Genetic medicine research

Where LogicBio Therapeutics is headquartered

Location

Headquarters

HQ city
Foster City
HQ country
United States
HQ region
North America

Offices1 record

Markets served

LogicBio Therapeutics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Operations

Revenue model

  1. Gene therapy product revenue: LogicBio Therapeutics generated revenue through the development and commercialization of gene therapy treatments for genetic diseases.

LogicBio Therapeutics product offering

Product offering

Core offering

LogicBio Therapeutics developed gene therapy vectors and genome editing treatments targeting rare genetic and infectious diseases. The company leveraged proprietary AAV-based delivery technology to create therapies for previously incurable inherited conditions, operating as a clinical-stage genetic medicine company prior to its 2022 acquisition by Alexion.

Product overview

LogicBio Therapeutics was a genetic medicine company that developed genome editing and gene therapy treatments for genetic diseases. The company operated from Lexington, Massachusetts. In 2022, LogicBio was acquired by Alexion (AstraZeneca Rare Disease). The company had approximately $43 million in revenue and was developing treatments in the gene therapy space. Fred Chereau served as President and CEO of LogicBio prior to the acquisition.

Differentiator

Problem solved

Functional benefit

Products and services

  • Gene Therapy Treatments LogicBio Therapeutics developed gene therapy treatments for patients with rare genetic diseases, leveraging proprietary genome editing and AAV-based delivery technology to address previously incurable inherited conditions.
  • Genome Editing Technologies LogicBio Therapeutics' proprietary genome editing technologies formed a core component of the company's genetic medicine platform for treating rare genetic diseases, including genome editing approaches such as those for rare inherited disorders.

Companies that use LogicBio Therapeutics

Customer profile

Segments1 record

Ideal customer profiles1 record

LogicBio Therapeutics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

LogicBio Therapeutics partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • AlexioncoreStrategic or Co-development Partner · 1 January 2022LogicBio Therapeutics was acquired by Alexion in 2022. This acquisition brought LogicBio's gene therapy capabilities under Alexion's rare disease portfolio, with former LogicBio CEO Fred Chereau transitioning to Senior Vice President at Alexion - AstraZeneca Rare Disease and subsequently to CEO of Sensorion.

Scale indicators4 records

Recent moves6 records

Expansion highlights3 records

LogicBio Therapeutics competitors and assessment

Company assessment

Direct peers

  • CRISPR Therapeutics: Pioneer in CRISPR/Cas9 genome editing therapeutics for rare genetic diseases including sickle cell disease and beta thalassemia. Directly comparable gene editing platform approach with overlapping indications.
  • bluebird bio: Direct competitor developing gene therapies and genome editing approaches for rare genetic diseases, including hemoglobinopathies and neurological conditions. Highly comparable in modality, indication focus, and target patient population.
  • uniQure: Gene therapy company focused on AAV-based treatments for rare diseases, including CNS and metabolic disorders. Directly comparable platform approach targeting monogenic conditions with high unmet need.
  • Editas Medicine: Genome editing company developing CRISPR-based and engineered Cas9 therapies for rare genetic diseases including inherited retinal disorders. Comparable genome editing modality and rare disease focus.
  • Regenxbio: AAV gene therapy platform company developing treatments for rare diseases including retinal, metabolic, and neuromuscular conditions. Comparable AAV vector technology and rare disease focus.

Broad incumbents

  • Sarepta Therapeutics: Established gene therapy player with approved products for Duchenne muscular dystrophy. Broader incumbent with commercial rare disease gene therapy portfolio and significant revenue.
  • Spark Therapeutics (Roche): Acquired by Roche, Spark is a gene therapy pioneer (Luxturna) focused on rare inherited diseases. Larger platform with approved products, making it a broad incumbent in the rare disease gene therapy space.

Emerging players

  • Passage Bio: Clinical-stage AAV gene therapy company targeting rare CNS disorders. Comparable platform approach with similar stage of development and rare monogenic disease focus.
  • GenSight Biologics: Gene therapy company developing AAV-based treatments for rare ophthalmologic and CNS diseases. Comparable modality (AAV gene therapy) and rare disease positioning.
  • Taysha Gene Therapies: Clinical-stage gene therapy company developing AAV-based treatments for rare CNS diseases. Comparable platform, similar rare disease focus, and overlapping patient populations.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks4 records

Key highlights5 records

Customer concentration

LogicBio Therapeutics social profiles

Digital presence

LogicBio Therapeutics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

LogicBio Therapeutics leadership team

Management profile

Number of profiles

LogicBio Therapeutics funding detail

Funding detail

Funding overview

Funding rounds5 records

Investors8 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

LogicBio Therapeutics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about LogicBio Therapeutics

What does LogicBio Therapeutics do?

LogicBio Therapeutics developed gene therapy vectors and genome editing treatments targeting rare genetic and infectious diseases. The company leveraged proprietary AAV-based delivery technology to create therapies for previously incurable inherited conditions, operating as a clinical-stage genetic medicine company prior to its 2022 acquisition by Alexion.

Is LogicBio Therapeutics a public or private company?

LogicBio Therapeutics is a public company. It is classified as corporate owned and is currently acquired.

When was LogicBio Therapeutics founded?

LogicBio Therapeutics was founded in 2015. It employs 51 to 100 people.

Where is LogicBio Therapeutics based?

LogicBio Therapeutics is headquartered in Foster City, United States, in the North America region.

How does LogicBio Therapeutics make money?

One revenue line is on record: gene therapy product revenue.

Who are LogicBio Therapeutics's main competitors?

Direct peers on record are CRISPR Therapeutics, bluebird bio, uniQure, Editas Medicine and Regenxbio. Broad incumbents are Sarepta Therapeutics and Spark Therapeutics (Roche). Emerging players are Passage Bio, GenSight Biologics and Taysha Gene Therapies.

Does LogicBio Therapeutics have an API?

No public API is recorded for LogicBio Therapeutics.

What industry is LogicBio Therapeutics in?

LogicBio Therapeutics's product category is Gene Therapy & Genome Editing Therapeutics. Its primary akta.pro industry code is HLAAACAE, Gene Therapy for Rare/Monogenic Diseases, with a secondary code of HLAAACAA, AAV Vector Gene Therapy Developers. Its NAICS code is 541714 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Ticker ReportLogicBio Therapeutics (OTCMKTS:LOGC) Releases Earnings Results, Misses Estimates By $0.10 EPSLogicBio Therapeutics reported a quarterly loss of $0.14 per share, missing analyst estimates of a $0.04 loss by $0.10, while matching revenue consensus at $36 million. Goldman Sachs Group Inc. significantly increased its stake in the company, raising holdings by 284.9% during the first quarter.Defense WorldLogicBio Therapeutics (LOGC) to Release Quarterly Earnings on ThursdayLogicBio Therapeutics is scheduled to release its Q2 2026 earnings results on Thursday, August 6th, with analysts projecting a loss of $0.0414 per share on revenue of $22.4760 million. Goldman Sachs Group Inc. recently increased its stake in the company by 284.9% during Q1, acquiring 389,843 additional shares for a total position worth approximately $3.68 million. The genetic medicine company, which focuses on genome editing and gene therapy treatments using its GeneRide and sAAVy platforms, has a market capitalization of $445.75 million and trades on the OTCMKTS.Defense WorldHead to Head Contrast: LogicBio Therapeutics (OTCMKTS:LOGC) & MYT Netherlands Parent B.V. (NYSE:MYTE)This article presents a side-by-side financial comparison of LogicBio Therapeutics and MYT Netherlands Parent B.V., contrasting metrics including revenue ($43M vs $881M), earnings per share, valuation ratios, institutional ownership, and profitability measures.Defense WorldReviewing Onion Global (NYSE:OG) & LogicBio Therapeutics (OTCMKTS:LOGC)This article provides a comparative financial analysis of Onion Global and LogicBio Therapeutics, examining metrics including revenue, earnings, valuation, profitability, ownership structures, and stock volatility. Onion Global reported $2.04 billion in revenue versus LogicBio's $43 million, though both companies showed negative net income ($-55.9 million and $-29 million respectively). The piece also includes brief company descriptions noting Onion Global operates a lifestyle brand platform in China while LogicBio Therapeutics is a genetic medicine company developing gene therapy treatments.BioSpaceAlexion, AstraZeneca Rare Disease, Completes Acquisition of LogicBio® TherapeuticsAlexion, AstraZeneca Rare Disease has completed its acquisition of LogicBio Therapeutics, a genomic medicine company, through a merger following the satisfaction of all tender offer conditions. The transaction involves paying $2.07 per share for LogicBio stock and includes the appointment of LogicBio CEO Frederic Chereau as Senior Vice President at Alexion to advance rare disease R&D. This move is intended to accelerate Alexion's growth in genomic medicines by leveraging LogicBio's unique technology and pre-clinical development expertise.BenzingaShort Volatility Alert: LogicBio Therapeutics, Inc. - CONTEXTLOGIC HOLDINGS INC by ContextLogic HoldingsOn November 4, 2022, Tidal Markets in partnership with Benzinga Insights detected unusual short-selling activity in LogicBio Therapeutics, Inc. (NASDAQ:LOGC) shares, with a volatility change of +102.26% pushing the volatility indicator to 7.928.FinSMEsAlexion, AstraZeneca Rare Disease to Acquire LogicBio TherapeuticsAlexion, AstraZeneca Rare Disease acquired LogicBio Therapeutics, a clinical-stage genomic medicine company, via a cash tender offer at $2.07 per share. The deal is expected to close in four to six weeks, subject to a majority tender and other conditions, with LogicBio employees retained at their current location.PR NewswireINVESTOR ALERT: The M&A Class Action Firm Announces the Investigation of LogicBio Therapeutics, Inc. - LOGCLaw firm Monteverde & Associates PC announced an investigation into the proposed acquisition of LogicBio Therapeutics, Inc. by AstraZeneca Rare Disease at $2.07 per share in cash, representing a premium over the stock's prior trading price. The firm is reaching out to LOGC shareholders to offer free information about the deal and potential legal protection. This type of M&A class action investigation is a routine practice when shareholders may believe they are receiving inadequate consideration for their shares.PR NewswireSHAREHOLDER ALERT: Weiss Law Investigates LogicBio Therapeutics, Inc.Weiss Law has launched an investigation into the proposed acquisition of LogicBio Therapeutics, Inc. by AstraZeneca Rare Disease (Alexion) via tender offer, questioning whether the $2.07 per-share cash consideration adequately compensates shareholders. The law firm is examining whether the board of directors breached fiduciary duties and whether full disclosure regarding the sales process and valuation has been made. Notably, at least one analyst set a price target of $2.50 per share, representing a $0.43 premium over the offered merger consideration.PR NewswireShareholder Alert: Ademi LLP investigates whether LogicBio® Therapeutics, Inc. has obtained a Fair Price in its transaction with AstraZenecaAdemi LLP is investigating LogicBio Therapeutics regarding its transaction with AstraZeneca, alleging potential breaches of fiduciary duty by the board. The firm contends that the $2.07 per share cash tender offer is unfair and that restrictive terms prevent competing bids while insiders receive substantial change-of-control benefits. This legal action challenges whether shareholders are receiving a fair price for their shares in the acquisition.